Asbestos-associated genome-wide DNA methylation changes in lung cancer

International Journal of Cancer

Volumn 141, Issue 10, 2017, Pages 2014-2029

  Kettunen, Eeva ^a   Hernandez Vargas, Hector ^b   Cros, Marie Pierre ^b   Durand, Geoffroy ^b   Le Calvez Kelm, Florence ^b   Stuopelyte, Kristina ^c,d   Jarmalaite, Sonata ^c,d   Salmenkivi, Kaisa ^e   Anttila, Sisko ^a,e   Wolff, Henrik ^a   Herceg, Zdenko ^b   Husgafvel Pursiainen, Kirsti ^a  

^a FINNISH INSTITUTE OF OCCUPATIONAL HEALTH   (Finland)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c VILNIUS UNIVERSITY   (Lithuania)

^d National Cancer Institute   (Lithuania)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

asbestos exposure; DNA methylation arrays; lung cancer; pyrosequencing; smoking

Indexed keywords

ASBESTOS; DNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL 3; TUMOR MARKER;

ARTICLE; BEND4 GENE; CANCER RISK; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; GENE; GENOME; GLT25D2 GENE; GPR135 GENE; HUMAN; HUMAN TISSUE; LUNG CANCER; MALE; NPTN GENE; NRG2 GENE; PRIORITY JOURNAL; PYROSEQUENCING; RARB GENE; RISK FACTOR; SMOKING; TPO GENE; TRPC3 GENE; ZSCAN31 GENE; CASE CONTROL STUDY; FOLLOW UP; GENETIC EPIGENESIS; GENETICS; GENOME-WIDE ASSOCIATION STUDY; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS;

ASBESTOS; BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FOLLOW-UP STUDIES; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LUNG NEOPLASMS; MALE; PROGNOSIS;

EID: 85026665228     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.30897     Document Type: Article

References (50)

1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer, 2013. Available at: http://globocan.iarc.fr, accessed on February 02, 2017.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Personal habits and indoor combustions. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt. E):1–538.
3. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum 2012;100C:219–309.
4. Kameda T, Takahashi K, Kim R, et al. Asbestos: use, bans and disease burden in Europe. Bull World Health Organ 2014; 92:790–7.
5. Takahashi K, Landrigan PJ, Collegium Ramazzini. The Global health dimensions of asbestos and asbestos-related diseases. Ann Glob Health 2016;82:209–13.
6. Mossman BT, Lippmann M, Hesterberg TW, et al. Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health 2011; 14:76–121.
7. Kettunen E, Aavikko M, Nymark P, et al. DNA copy number loss and allelic imbalance at 2p16 in lung cancer associated with asbestos exposure. Br J Cancer 2009; 100:1336–42.
8. Nymark P, Aavikko M, Mäkilä J, et al. Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. Mol Oncol 2013; 7:29–40.
9. Nymark P, Guled M, Borze I, et al. Integrative analysis of microRNA, mRNA and aCGH data reveals asbestos- and histology-related changes in lung cancer. Genes Chromosomes Cancer 2011; 50:585–97.
10. Irizarry RA, Ladd-Acosta C, Wen B, et al. The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat Genet 2009; 41:178–86.
11. Yang X, Han H, De Carvalho DD, et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 2014; 26:577–90.
12. Feil R, Fraga MF. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet 2012; 13:97–109.
13. Herceg Z, Lambert MP, van Veldhoven K, et al. Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis 2013; 34:1955–67.
14. Jarmalaite S, Kannio A, Anttila S, et al. Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer. Int J Cancer 2003; 106:913–8.
15. Scesnaite A, Jarmalaite S, Mutanen P, et al. Similar DNA methylation pattern in lung tumours from smokers and never-smokers with second-hand tobacco smoke exposure. Mutagenesis 2012; 27:423–9.
16. Christensen B, Houseman E, Godleski J, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009; 69:227–34.
17. Andujar P, Wang J, Descatha A, et al. p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer 2010; 67:23–30.
18. Dammann R, Strunnikova M, Schagdarsurengin U, et al. CpG island methylation and expression of tumour-associated genes in lung carcinoma. Eur J Cancer 2005; 41:1223–36.
19. Kim D, Nelson H, Wiencke J, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61:3419–24
20. Teschendorff AE, Gao Y, Jones A, et al. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nat Commun 2016; 7:10478.
21. Karjalainen A, Anttila S, Heikkilä L, et al. Asbestos exposure among Finnish lung cancer patients: occupational history and fiber concentration in lung tissue. Am J Ind Med 1993; 23:461–71.
22. Vaissière T, Hung R, Zaridze D, et al. Quantitative analysis of DNA methylation profiles in lung cancer identifies aberrant DNA methylation of specific genes and its association with gender and cancer risk factors. Cancer Res 2009; 69:243–52.
23. Joehanes R, Just AC, Marioni RE, et al. Epigenetic signatures of cigarette smoking. Circ Cardiovasc Genet 2016; 9:436–47.
24. Roessler J, Ammerpohl O, Gutwein J, et al. Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina, Inc. BMC Res Notes 2012; 5:210
25. Fernandez AF, Assenov Y, Martin-Subero JI, et al. DNA methylation fingerprint of 1628 human samples. Genome Res 2012; 22:407–19.
26. Hansen KD, Timp W, Bravo HC, et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43:768–75.
27. Sun M, Behrens C, Feng L, et al. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res 2009; 15:4829–37.
28. Owczarek S, Kiryushko D, Larsen MH, et al. Neuroplastin-55 binds to and signals through the fibroblast growth factor receptor. FASEB J 2010; 24:1139–50.
29. Shapovalov G, Lehen'kyi V, Skryma R, et al. TRP channels in cell survival and cell death in normal and transformed cells. Cell Calcium 2011; 50:295–302.
30. Kamp DW, Liu G, Cheresh P, et al. Asbestos-induced alveolar epithelial cell apoptosis. The role of endoplasmic reticulum stress response. Am J Respir Cell Mol Biol 2013; 49:892–901.
31. Cipollini M, Pastor S, Gemignani F, et al. TPO genetic variants and risk of differentiated thyroid carcinoma in two European populations. Int J Cancer 2013; 133:2843–51.
32. Upadhyay D, Kamp D. Asbestos-induced pulmonary toxicity: role of DNA damage and apoptosis. Exp Biol Med 2003; 228:650–9.
33. Lam TK, Rotunno M, Ryan BM, et al. Heme-related gene expression signatures of meat intakes in lung cancer tissues. Mol Carcinog 2014; 53:548–56.
34. Mori Y, Olaru AV, Cheng Y, et al. Novel candidate colorectal cancer biomarkers identified by methylation microarray-based scanning. Endocr Relat Cancer 2011; 18:465–78.
35. Cardenas H, Vieth E, Lee J, et al. TGF-beta induces global changes in DNA methylation during the epithelial-to-mesenchymal transition in ovarian cancer cells. Epigenetics 2014; 9:1461–72.
36. Li X, Hawkins GA, Ampleford EJ, et al. Genome-wide association study identifies TH1 pathway genes associated with lung function in asthmatic patients. J Allergy Clin Immunol 2013; 132:313–20. e315
37. Anglim PP, Alonzo TA, Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 7:81.
38. Baird BN, Schliekelman MJ, Ahn YH, et al. Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. PLoS One 2013; 8:e67054.
39. Powrozek T, Krawczyk P, Kucharczyk T, et al. Septin 9 promoter region methylation in free circulating DNA-potential role in noninvasive diagnosis of lung cancer: preliminary report. Med Oncol 2014; 31:917.
40. Tan SX, Hu RC, Liu JJ, et al. Methylation of PRDM2, PRDM5 and PRDM16 genes in lung cancer cells. Int J Clin Exp Pathol 2014; 7:2305–11.
41. Tessema M, Yingling CM, Snider AM, et al. GATA2 is epigenetically repressed in human and mouse lung tumors and is not requisite for survival of KRAS mutant lung cancer. J Thorac Oncol 2014; 9:784–93.
42. Carvalho RH, Haberle V, Hou J, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin 2012; 5:9.
43. Dogan MV, Shields B, Cutrona C, et al. The effect of smoking on DNA methylation of peripheral blood mononuclear cells from African American women. BMC Genomics 2014; 15:151.
44. Monick MM, Beach SR, Plume J, et al. Coordinated changes in AHRR methylation in lymphoblasts and pulmonary macrophages from smokers. Am J Med Genet B Neuropsychiatr Genet 2012; 159B:141–51.
45. Breitling LP, Yang R, Korn B, et al. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. Am J Hum Genet 2011; 88:450–7.
46. Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associated with tobacco smoking in human cancer. Science 2016; 354:618–22.
47. Allione A, Marcon F, Fiorito G, et al. Novel epigenetic changes unveiled by monozygotic twins discordant for smoking habits. PLoS One 2015; 10:e0128265.
48. Huang T, Chen X, Hong Q, et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep 2015; 5:8897.
49. Li X, Liu Y, Salz T, et al. Whole-genome analysis of the methylome and hydroxymethylome in normal and malignant lung and liver. Genome Res 2016; 26:1730–41.
50. Leenen FA, Muller CP, Turner JD. DNA methylation: conducting the orchestra from exposure to phenotype? Clin Epigenetics 2016; 8:92.